FDA Plants OB-GYNs on Implant Addiction Therapy Committee; Titan Harvests Yes Vote
This article was originally published in RPM Report
Executive Summary
An advisory committee reviewing Titan’s Probuphine for abuse dependence leaned heavily on reassuring safety perspectives of two guest members invited for their particular expertise. No, they weren’t addiction experts. They were gynecologists.
You may also be interested in...
We Don’t Kick Diabetics Out for Eating Ice Cream: Issues With Efficacy in Addiction Therapy
An Advisory Committee review of Titan’s Probuphine highlights the difficulties of measuring addiction treatment products: how to quantify success when even opioid-positive urine samples can be a good sign.
Wyeth Discontinues Norplant: Contraception Removals Reimbursed To Dec. 31
Wyeth will pay for removal procedures for the Norplant contraceptive through the end of 2002, the company says in a "Dear Doctor" letter issued July 26
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.